
Entrectinib is a kinase inhibitor that targets both the NTRK and ROS1 oncogenes. This study shows that NTRK and ROS1 fusions are present in 46% and 64% of blood samples from patients enrolled on a clinical trial, with a response rate of 72%. Genomic tumour profiling informs targeted treatment options. This study evaluated the clinical validity of F1L CDx as an aid in identifying patients with NTRK‐fp or ROS1‐fp tumours and assessed the genomic landscape pre-and post‐entrectinib treatment. It was concluded that F1L CDx is a clinically useful complement to tissue‐based testing to identify patients who may benefit from entrectinib and those with acquired resistance mutations associated with disease progression.
Like
Save
Share